STOCK TITAN
  1. Home
  2. Sec-filings
  3. OBIO
  4. [144] Orchestra BioMed Holdings, Inc. SEC Filing

Orchestra BioMed (NASDAQ: OBIO) insider details Rule 144 sales of 45,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Orchestra BioMed Holdings Inc. (OBIO) has a shareholder filing to sell common stock under Rule 144. The filing lists a planned sale of 15,000 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $61,291.68, to be sold on or after August 3, 2026 on NASDAQ. These shares were acquired from the issuer as restricted stock vesting on November 25, 2024 as compensation. The reporting shareholder, Darren Sherman, also reports prior sales during the last three months of 15,000 shares of common stock on June 1, 2026 for $58,049.53 and 15,000 shares on July 1, 2026 for $64,066.02.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 15,000 shares Common stock to be sold on or after August 3, 2026
Planned sale value $61,291.68 Aggregate market value for 15,000 shares via Fidelity Brokerage Services LLC
Shares sold June 1, 2026 15,000 shares Common stock sold for aggregate consideration of $58,049.53
Proceeds June 1, 2026 sale $58,049.53 Aggregate consideration for 15,000 common shares
Shares sold July 1, 2026 15,000 shares Common stock sold for aggregate consideration of $64,066.02
Proceeds July 1, 2026 sale $64,066.02 Aggregate consideration for 15,000 common shares
Acquisition date of restricted stock November 25, 2024 Restricted stock vesting from issuer as compensation
Planned sale earliest date August 3, 2026 Earliest date listed for NASDAQ sale under Rule 144
Rule 144 regulatory
"has a shareholder filing to sell common stock under Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting financial
"These shares were acquired from the issuer as restricted stock vesting"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
compensation financial
"acquired from the issuer as restricted stock vesting on November 25, 2024 as compensation"
aggregate consideration financial
"15,000 shares of common stock on June 1, 2026 for $58,049.53 aggregate consideration"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What does the OBIO Rule 144 filing disclose about planned stock sales?
The filing discloses a planned sale of 15,000 shares of Orchestra BioMed (OBIO) common stock. These shares, valued at $61,291.68, are expected to be sold on or after August 3, 2026 on NASDAQ through Fidelity Brokerage Services LLC.

Who is selling Orchestra BioMed (OBIO) shares in this Rule 144 notice?
The Rule 144 notice lists Darren Sherman as the shareholder associated with the sales. He reports past sales and a planned sale of 15,000 shares of OBIO common stock acquired through restricted stock vesting as compensation.

How many OBIO shares has the filer sold in the past three months?
The filer reports selling 15,000 shares of Orchestra BioMed common stock on June 1, 2026 for $58,049.53 and another 15,000 shares on July 1, 2026 for $64,066.02, totaling 30,000 shares over that period.

At what prices were the recent OBIO stock sales reported in the Rule 144 filing?
The filing lists aggregate proceeds of $58,049.53 for 15,000 shares sold on June 1, 2026, and $64,066.02 for 15,000 shares sold on July 1, 2026, reflecting the total consideration for each transaction.

How were the Orchestra BioMed (OBIO) shares being sold under Rule 144 originally acquired?
The filing states the 15,000 shares planned for sale were acquired from the issuer on November 25, 2024 through restricted stock vesting, categorized as compensation to the shareholder.

Through which broker will the planned OBIO Rule 144 sale be executed?
The planned sale of 15,000 OBIO shares is listed to occur through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, with trading expected on NASDAQ on or after August 3, 2026.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR